Table 1.
Patients with high EDSS (4.0‒6.0) in the SPECTRIMS and PRISMS studies
| Treatment received | PRISMS (n = 371) | SPECTRIMS (n = 409) | PRISMS/SPECTRIMS pooled (n = 335) | ||||
|---|---|---|---|---|---|---|---|
| N per treatment | n (% with high EDSS) | N per treatment | n (% with high EDSS) | N per treatment | n (% from PRISMS) | n (% from SPECTRIMS) | |
| Placebo | 187 | 28 (15.0) | 205 | 136 (66.3) | 164 | 28 (17.1) | 136 (82.9) |
| sc IFN β-1a 44 µg tiw | 184 | 31 (16.8) | 204 | 140 (68.6) | 171 | 31 (18.1) | 140 (81.9) |
EDSS Expanded Disability Status Scale, IFN β-1a interferon beta-1a, sc subcutaneous, tiw three times weekly